Compare Msci Inc (MSCI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Tango Therapeutics Inc. — how do they compare? Msci Inc trades at $560.52 (market cap $41.29B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Msci Inc is far larger — about 11× Tango Therapeutics Inc.'s market cap, and Msci Inc pays a 1.44% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 83 Days and Tango Therapeutics Inc. for 0 Days on average.
| MSCI | TNGX | |
|---|---|---|
Market Cap | $41.29B | $3.75B |
Volume | 468,436 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $643.83 | $32.90 |
52-Week Low | $511.84 | $7.50 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $47.46B | $2.77B |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $560.52, down 1.32% today, with strong profitability (40.73% net margin) and consistent revenue growth from $2.2B in 2022 to $3.1B in 2025. Recent Q2 2026 earnings missed expectations at $4.94 EPS, but Q1 and Q4 2025 beat. Technicals show a bullish moving average signal with RSI at 59.48 neutral, while analyst consensus is strongly bullish with a $701.71 price target. The company maintains robust cash flow from operations of $1.6B in 2025.
Outlook remains positive driven by recurring revenue streams and market position, though high valuation (P/E 31.06) and debt levels ($4.51B long-term) pose risks. The upcoming Q3 2026 earnings on October 20, 2026, is a key catalyst. Investors should weigh strong fundamentals against premium pricing and macroeconomic sensitivity.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
